IFCT-2501 IDEATION ctDNA-guIDEd consolidATION immunotherapy after chemoradiotherapy in patients with stage III non-small cell lung cancer

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522801-39-00

Enrollment

177

Registered

2026-07-02

Start date

Unknown

Completion date

Unknown

Last updated

2026-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stage III Non Small Cell Lung Cancer

Brief summary

12-month PFS rate from randomization as assessed by an independent review committee.

Detailed description

Investigator-assessed PFS from randomization, OS from randomization., Incidence, nature, and severity of adverse events, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 6.0 (NCI CTCAE v6.0)., Global and specific quality of life questionnaires QLQ-C30 QLQ-LC29 and EQ-5D-5L.

Interventions

DRUGIMFINZI 50 mg/mL concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
12-month PFS rate from randomization as assessed by an independent review committee.	—

Secondary

Measure	Time frame
Investigator-assessed PFS from randomization, OS from randomization., Incidence, nature, and severity of adverse events, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 6.0 (NCI CTCAE v6.0)., Global and specific quality of life questionnaires QLQ-C30 QLQ-LC29 and EQ-5D-5L.	—

Outcome results

None listed

Source: EU CTIS · Data processed: Jul 3, 2026